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Abstract
Rotator cuff injuries (RCIs) present a major health problem due to high incidences of degenerative tears greater than 3 cm and
prevalence of re-tears following surgical procedures. Since healing and functional restoration relies upon bone ingrowth into the
tendon, it is hypothesised that sustained delivery of osteoinductive factors including bone morphogenetic proteins (BMPs),
specifically BMP2–7, may significantly improve RCI tendon-bone healing. Here, growth factor candidates and delivery mech-
anisms are reviewed, specifically for improved RCI healing through enhanced bone ingrowth. In addition to BMPs, other
potentially osteogenic factors including platelet-derived growth factors (PDGF), fibroblast growth factor (FGF), transforming
growth beta isoforms (TGF-β1 and TGF-3) and parathyroid hormone (PTH) are evaluated since they can induce bone formation
at the healing tendon attachment site. Several challenges must be addressed prior to clinical translation. Themajority of published
studies utilise in vivo animal models. In general, BMP-7 demonstrates a stronger stimulating effect when compared to BMP-2;
the reported effectiveness of BMP-2 is often conflicting. Alternative factors, including PDGF and PTH, also demonstrate
potential for assisting bone growth in enthesis healing. The use of sustained and biomimetic delivery systems appears to have
the greatest positive effects. Some studies have demonstrated a dose-dependent effect, in conjunction with varying age, indicating
that stratified therapies could be a viable solution for RCI healing. To adequately resolve potential treatments for RCI, further
expanded and correlated animal trials must be undertaken, and indicative human trials are required with consideration of surgical
and patient-specific influences.
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Introduction
Rotator cuff tears are a highly prevalent musculoskeletal inju-
ry (Fig. 1); more than 200,000 repair procedures are per-
formed annually in the USA alone, resulting in an estimated
$474 million in health care costs [1]. Furthermore, there is a
high prevalence of structural failures post repair, with surgi-
cally repaired tendons prone to a high rate of re-tear (between
20 and 95%) [1]. It is known that rotator cuff healing occurs in
3 stages: inflammation, repair, and remodelling. Upon com-
pletion of the healing process, the normal rotator cuff enthesis
(osteotendinous unit) fails to regenerate [2]. Following repair,
rotator cuff tendon healing is often limited by a deficit in tissue
formation, with gap formation at the repair site being a com-
mon occurrence. Hence, the tendon is weaker than the native
insertion site, which renders repairs prone to failure and, thus,
repeat injuries [3].
A review of experimental studies by Gulotta and Rodeo
(2009) established that bone ingrowth is vital to the healing
of the repaired rotator cuff tendon and bone [3]. With this in
mind, it has been hypothesised that the administration of
osteoinductive agents could improve the healing of a tendon
attached to the bone surface and thus strengthen the repair [3].
As a result, there have been a number of studies aimed at
analysing the use of osteoinductive factors including bone
morphogenetic proteins, e.g. BMP-2 through 7; for rotator
cuff enthesis healing [1]. Promising results using osteoinductive
factors to improve tendon healing have been reported both
in vitro and in vivo, although the majority of studies are reliant
upon the use of animal models [4]. However, peer-reviewed
This article is part of the Topical Collection on Medicine
* Samantha L. Wilson
s.wilson2@lboro.ac.uk
1 National Centre for Sport and Exercise Medicine, School of Sport,
Exercise and Health Sciences, Loughborough University, Epinal
Way, Loughborough, Leicestershire LE11 3TU, UK
2 Centre for Biological Engineering, Wolfson School of Mechanical,
Electrical and Manufacturing Engineering, Loughborough
University, Epinal Way, Loughborough, Leicestershire LE11 3TU,
UK
SN Comprehensive Clinical Medicine (2019) 1:267–276
https://doi.org/10.1007/s42399-019-0041-z
reports, which evaluate osteoinductive growth factors specifi-
cally for rotator cuff injuries, remain limited [5–10]; and there
has yet to be a study that evaluates the effectiveness of growth
factors in the treatment of rotator cuff injuries (RCIs) in
humans [11].
Within the existing literature, it has become apparent that
multiple factors play a role when attempting to optimise the
dosage of growth factors for therapeutic applications.
Determining the most effective factor or combination of fac-
tors, the optimum dose, timing, and vehicle for delivery,
whilst maintaining their localisation and intended bioactivity
at the injury site, is a requisite [1]. When assessing whether an
intervention is successful in impacting healing in RCI, the
effects of surgery and general condition of the patient, animal
or human, is an important consideration. Potential factors
which can affect healing have been extensively studied and
reviewed [12–14] and should be listed in any report to enable
true comparisons between studies (Table 1).
Identifying the most appropriate preclinical model to eval-
uate the strategy is also necessary as no single animal model is
capable of reproducing all of the features of the human injury,
and hence, this review aims to compare the current strategies
that have used osteoinductive growth factors specifically for
injuries of the rotator cuff, with some inference from the sim-
ilar anterior cruciate ligament (ACL), to identify the most
promising methods for biological augmentation. BMPs 12–
14, also known as growth differentiation factors (GDFs) 5–7
are distinct from the osteoinductive BMPs (BMP-2, BMP-4,
BMP-7) in the sense that they promote tendon and
fibrocartilage formation [3] and not bone and, hence, will
not be evaluated in this review.
Comparison of Delivery Vehicles for Growth
Factor Therapies
Due to their short half-life, and a low specificity in vivo [85]
determining how to regulate growth factor activity is vital when
developing therapeutic treatments. There are several methods
that have been investigated both in vivo and in vitro with the
specific aim of promoting a sustained, localised release of
growth factors at the injury site.
In Vivo Models
In an early study by Rodeo (2007), an Bosteoinductive bone
marrow protein extract^ comprised of proteins BMP-2
through 7, transforming growth factor beta 1 to 3 (TGF-β1–
3), and basic fibroblast growth factor (b-FGF) were delivered
as a growth factor mixture via a collagen sponge, in an ovine
infraspinatus tendon detachment model [5]. Rodeo
hypothesised that this could improve the healing of a tendon
attached to the bone surface as it would induce greater bone
ingrowth [5]. New bone and soft tissue formation were
analysed via radiographs, magnetic resonance imaging
(MRI), and histological analysis at 6 and 12 weeks. In com-
parison to the control groups, the specimens that had received
growth factor treatment demonstrated significantly higher
levels of new bone formation (not present in controls) and
newly formed soft tissue in the tendon-bone gap. Tensile test-
ing revealed that the ultimate load-to-failure was significantly
greater following growth factor treatment, when compared to
collagen implants alone at 6 weeks [5]. However, these failure
loads were only approximately 31% of the normal tendon
strength; this could be due to the disorganised reparative ma-
trix resulting in inferior biomechanical properties.
Furthermore, the authors postulated that the collagen sponge
implant may have elicited a subtle immune response that was
detrimental to new tissue formation. This highlights the im-
portance of the appropriate selection and need to understand
the kinetics of the delivery scaffold.
In a following study, Kovacevic and Rodeo (2008) discuss
two sheep model studies, observing the effect of mixed fibro-
blast growth factor (FGF) and BMP-2 through 7 and BMP-12
in various delivery vehicles. Akin to the previously reported
studies in ovine models (suture through bone tunnel), it was
observed that scar tissue formed within the gap between ten-
don and bone; however, the mixture created a more robust
fibrocartilaginous zone in comparison to controls.
Intervention with BMP-12 resulted in increased load-to-
failure ratios and stiffness (up to three times greater) after
8 weeks. From histological evaluation of the groups, re-
establishment of the collagen fibre continuity between the
bone and enthesis scar tissue was observed. Increased content
of glycosaminoglycans (GAGs) was also present suggesting
fibrocartilage formation [86].Fig. 1 Rotator cuff tear and gap formation
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As an isolated component, BMP-7 has been reported to
induce cell differentiation into chondrocytes and stimulate
cartilage matrix production when delivered to the shoulder
joint of rats [8]. It was hypothesised that the use of a cross-
linked gelatine hydrogel sheet (GHS) would maintain a
sustained release and localised concentration of BMP-7, thus
promoting rotator cuff repair. In comparison to controls,
whereby BMP-7 was administered to the subacromial bursa
via injection, GHS impregnated with BMP-7 and implanted
onto tendon demonstrated significantly improved enthesis
matrix production and, as a result, improved tendon-to-bone
maturation scores and biomechanical properties [8]. Thus, the
use of gelatine hydrogels, which are approved for clinical
applications, provide an economical, customisable scaffold
for the sustained release of BMP-7 for up to several weeks
and a viable solution for RCI repair.
In addition to the use of hydrogel scaffolds, the use of
biological patches has been investigated as an alternative de-
livery solution, particularly for large tears and rotator cuff
repairs that have been deemed Birreparable^ [87]. Lee et al.
(2016) first reported the use of a dermal patch isolated from a
human cadaver, to deliver BMP-2 [10]. In the study, a rhBMP-
2-coated dermal patch (1 cm × 2 cm) was inserted in a leporine
model of chronic RCI. The purpose was to evaluate the
Table 1 Factors which affect healing of rotator cuff healing
Surgical
Repair technique Open vs arthroscopic [15–18]
Single or double row suture [19–22]
Medial knots or knotless [23–25]
Suture anchor Material, design, size, loaded suture material/numbers, location, configuration [26, 27]
Greater tuberosity
preparation
Considered to be standard procedure,
however positioning of shoulder may be detrimental in osteoporotic bone anchor fixation [12, 28–30]
Acrominosplasty Removal of acromial spur in response to full thickness tear is commonplace;
although optimal timing of acrominoplasty remains unclear [12, 31–34]
Augmentation Use of patches: material, sizes vary [35–39]
Platelet-rich plasma [40–43]
Cell therapy (e.g. mesenchymal stem cells) [44–47]
Post-operative
rehabilitation
Can be modified based on surgeon preference, tear size, location, and quality of repair [12, 48, 49]
Removal of load [50, 51]
Onset, number of therapy visits, duration of follow-up [49, 52, 53]
Early vs delayed motion/immobilisation [12, 54–56]
Patient specific
Age Average age of unilateral tear—59 years; bilateral tears—68 years.
Inferior healing environment in older patients [12, 57]
Healing environment Presence of factors which negatively affect repair tissue (e.g. MMP-1, MMP-9, TNFα);
which positively affect repair (e.g. inhibitors of aforementioned molecules, BMPs, TGF-β)
Tear characteristics Larger size, fatty infiltration, and/or atrophy all negatively impact healing [12, 58]
Number of tendons involved
Recurrent vs preoperative tear size
Normal vs degenerative/delaminated tissue; fatty infiltration and atrophy often correlates with poor functional/clinical
outcome and failed repair [58–60]
Amount of muscle-tendon unit retraction, the preoperative tendon length may act as a predictor of reparability [61, 62]
Timeline of symptoms Surgery > 1 year vs ≤ 1 year since onset
Bone mineral density
(BMD)
Normal vs osteoporosis (OP), vitamin D deficiency; reduced BMD, and OP may cause difficulties in achieving reliable
fixation, reduces tendon-bone insertion strength, and detrimentally affects healing [63, 64]. Vitamin D has been linked to
bone and muscle proliferation and healing [65, 66].
Pain control Nonsteroidal anti-inflammatory drugs (NSAIDs) vs narcotics use: NSAIDs are commonly prescribed following repair;
however, their effect on healing is conflicting in the literature [67–69] . Narcotics including opiates relieve post-operative
pain [70] but have undesirable side effects [71] so are not recommended for long term use [72]
Diabetes Diabetes can impair fibrocartilage formation and collagen organisation leading to post-operative wound complications
[73–76]
Smoking Smoking has been linked to increased risk and severity of rotator cuff tears [77, 78];
non-smokers have greater improvement of pain and post-operative results [79]
Hypercholesterolemia Hypercholesterolemia has been linked to an increased likelihood of rotator cuff tears and is detrimental to healing [80–84]
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effectiveness of the healing-inductive capacity of the biologi-
cal patch. The results demonstrated that the inserted rhBMP-
2-coated acellular dermal patch significantly improved new
bone formation and enhanced biomechanical properties in-
cluding ultimate tensile strength [10]. Although there are nu-
merous materials available for biological patches including
dermal matrices, xenogeneic intestinal submucosa or pericar-
dium, and ceramic- or polymer-based synthetics available [88,
89], the biomechanical properties of cadaveric acellular der-
mal matrices appear to be a better option; potentially due to the
maintenance and continuity of the inherent collagen structure.
However, irrespective of the delivery mechanism or material,
caution must be used with the sustained delivery of high-
dosage BMPs, since BMP-7, and more frequently BMP-2, is
often associated with complications including overabundant
bone growth and heterotrophic ossification (HO) [35–37, 90,
91] when used to treat musculoskeletal disorders.
In developmental biology, Indian Hedgehog (Ihh) and
parathyroid hormone (PTH)-related peptide (PTHrP) exist as
reciprocal mediators in a feedback loop to control both chon-
drogenesis and mineralisation of the growth plate and enthesis
[38, 39]. Taking cues from this, Hettrich et al. (2012) injected
114 Sprague-Dawley rats subcutaneously with 10 μg/kg of
rhPTH on the day of surgery. From this, increased mineral
content, bone volume, fibrocartilage, osteoblast presence,
and blood vessels, as well as more favourable collagen fibre
organisation, was observed after 56 days. Despite this, the
biomechanical properties of the interface did not improve,
suggesting either greater integration is needed or additional
stimuli to enhance these properties [92]. A follow-up study
by Duchman et al. (2016), utilising the same dosage and mod-
el in 108 rats, delayed the start of rhPTH injection until day 7
post-surgery to avoid the inflammatory phase. Two weeks
postoperatively, treated rats demonstrated significantly greater
load-to-failure than controls, although at 16 weeks, no signif-
icant differences were found [93].
In Vitro Models
Pauly (2012) aimed to investigate whether BMP-2 and BMP-
7 could positively affect human RC tenocytes in vitro [6]. The
tenocyte-like cells (TLCs) isolated from human supraspinatus
and the long head of the biceps were isolated and incubated
with the growth factors, alone and in combination. BMP-7
stimulated TLC activity, expression and production of colla-
gen-I, in a dose-dependent manner. BMP-2 also stimulated
collagen-I production in TLCs; however, cell activity de-
creased with higher dosages. The combination of BMP-2
and BMP-7 reduced all parameters in comparison to BMP-7
alone.
Klatte-Schultz (2013) postulated that inferior biological
characteristics of TLCs may contribute to diminished rotator
cuff healing [7]. In their study, the stimulation potential of
human supraspinatus TLCs was investigated. Cell count,
collagen-I expression, and protein synthesis, which are signif-
icant factors for the tendon-bone healing of the rotator cuff,
were all stimulated following the application of BMP-2 and
BMP-7 in 3D culture.
Critique of Growth Factor Therapies
for Rotator Cuff Repair
In Vivo Strategies
Despite in vivo studies, tendon repair studies by Rodeo (2007)
demonstrate that the use of a collagen sponge to deliver
osteoinductive factors had the greatest biomechanical strength
in comparison to the controls; it was observed that this tech-
nique consistently detached from the repair site with the gap
only becoming evident following MRI analysis [5]. This is an
important discovery since other investigators are using the
same model for evaluation [86, 94–96]. Although they were
unable to study healing of an intact tendon, the resultant model
of tendon-bone gap healing is clinically relevant due to the
reported high rate of gap formation between tendon-bone [97].
There are limitations to the animal model used in Rodeo’s
study, as the bone-forming potential of sheep is far greater
than that in humans. Another limitation is that the healing of
an acute repair was examined, which does not mimic the typ-
ical clinical situation. They also had a relatively small sample
size, resulting in low power for clinical comparisons.
Despite the initial positive outcome from the later sheep
model studies which utilised a mixture of fibroblast growth
factor (FGF) and BMP-2 through 7, and BMP-12; it was sug-
gested by Kovacevic and Rodeo (2008) that, following nor-
malisation of failure loads to tissue volume, that the enhanced
formation of fibrocartilage was actually poor-quality scar tis-
sue rather than true regeneration.
Kabuto et al (2015) used GHS, which allows for the pres-
ervation of the biological activity of BMP-7 [8]. The different
methods of growth factor application (injection vs. GHS im-
plant) demonstrated the efficacy of delivery when comparing
the GHS implant to local injection. This study also took into
consideration the lengthy process of rotator cuff healing;
hence, administered BMP-7 must exert a sustained effect.
The GHS is a good option, as its safety is approved for clinical
use and it is economically produced.
The sustained release of BMP-7 due to the GHS favourable
collagen fibre orientation corresponds to the findings by Pauly
(2012). The results also suggest that the GHS acted not only in
the sustained release of growth factors but also by itself in
tissue repair, similar to the collagen sponge in Rodeo’s
(2007) study. It is worth noting that Kabuto et al. did not
observe any evidence of HO through microcomputed tomog-
raphy (μCT) analysis. The sustained release at a reduced
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dosage of BMP-7 may have reduced risk of formation, which
has been reported previously as local concentrations of BMP-
7 increase [36]. Kabuto et al. do, however, describe the limi-
tations of the study in which the specific anatomy of the mu-
rine model differs from the human shoulder. Additionally, re-
tear in rats has not been observed postoperatively, and as in the
previous model, it does not reflect degenerative tear as in
humans [50]. Despite this, the murine model is sufficiently
similar enough to continue to be used in in vivo studies [98].
The work by Lee (2017) is the first study to evaluate effects
of an acellular dermal patch combined with BMP-2 [10]. A
chronic RCI model was used, which, in comparison to other
published literature, is more representative of clinical injury.
Acellular dermal matrix has shown much better mechanical
support than any other ECM-based scaffolds [2]. However,
the biodegradation of the GHS must be investigated further
to optimise the healing and biomechanical outcomes.
Although rhBMP-2 has proven promising for tendon-bone
healing, many limitations still remain for the clinical applica-
tion based on safety and effectiveness; with conflicting evi-
dence from a previous study on stromal cells which showed
that rhBMP-2 led to impaired tendon-bone healing [9]. The
study was also limited in that it did not demonstrate the effec-
tiveness of various doses of rhBMP-2.
Hettrich et al. (2012) and Duchman (2016) investigated the
use of Ihh and PTHrP in rats. Both these studies used a dosage
based on previous literature, in which doses based in a range
that may be tolerated by humans were found to be effective in
enhancing fracture healing [99]. Although further optimisa-
tion of the timeline and dosage is obviously required, PTH
represents a feasible augmentation to current surgical inter-
ventions in the treatment of rotator cuff repair.
In Vitro Strategies
Pauly (2012) evaluated the effect of BMP-2 and BMP-7 on
human TLCs in vitro [6], unlike the aforementioned studies
which only used animal models. As it compared both growth
factors alone, it helped denote that overall, application of
BMP-7 led to better results than with BMP-2. It also demon-
strated that, the combined application of both showed de-
creased parameters when compared with BMP-7 alone; sug-
gesting that BMP-2 could possibly exert a negative influence
on the expression of BMP-7. Reports in this regard are con-
flicting; Tsai (2003) found a reduction in BMP-2 expression
by 40% under BMP-7 exposure [100]. On the contrary,
Nicklin (2000) reported upregulated BMP-2 expression after
BMP-7 exposure [101]. One possible explanation could be
that BMP-2 and BMP-7 partially bind to the same receptors,
and this could have led to competitive binding [6]. Pauly also
studied dose-dependent effects and found a maximum effect
for BMP-7 at dosages of 1000 ng/mL. This finding is in con-
trast to Yeh and Tsai (2008) who observed declining effects
beyond 100 ng/mL [102]. Differences in these studies could
be due to different cell origin, i.e. not rotator cuff, and/or
culture conditions. However, since the donor material was
obtained from torn rotator cuff cells, the study is more clini-
cally appropriate in comparison to using intact tendon.
One of the limitations of the previous study was that no
TLC characteristics for sub-groups were studied, which was
later investigated by Klatte-Schultz (2013), on TLCs from
rotator cuff of female donors [7]. Their findings correspond
to those with Pauly (2012), of a stronger stimulating effect
with BMP-7 than with BMP-2 [6]. Most importantly, the re-
sults were age-specific and indicated that possibly a higher
dosage of growth factors would be needed in older female
donors. This study, therefore, aimed to develop more
patient-specific therapy compared to uniform treatment of ro-
tator cuff tears. However, the study failed to link female sex to
inferior cuff healing; this could be due to the in vitro environ-
ment, which cannot mimic the role hormones play in the body.
Overall, BMP-7 has demonstrated a stronger stimulating
effect than BMP-2, which has been agreed upon by themajority
of published studies. On the contrary, the effectiveness of BMP-
2 has remarkable conflicting evidence, with some studies sug-
gesting reduction [6, 100] and some, reporting upregulation of
BMP-2 with exposure to BMP-7 in ACL repair (ACL), which
has very similar injury and repair mechanisms to RCI [101].
Lipner’s (2015) study makes a counter-argument stating that
rhBMP-2 led to impaired healing, but it can be argued that
BMP-2 in their study was delivered using a gene delivery ap-
proach, leading to a sustained, but uncontrolled dosage [9]. It is
possible that a different dose of BMP-2 may have been more
effective in improving tendon-to-bone healing. The study by
Pauly (2012) can be considered as the most demonstrative as
not only did they compare the growth factors in combination as
well as alone but also studied dose-dependent effect and used a
clinically relevant repair model. [6]
Alternative Growth Factors to Induce Osteogenesis
Whilst not traditionally used as an osteoinductive factor,
platelet-derived growth factor (PDGF) is a possible factor
for future consideration. It has also been shown to inhibit
osteoinduction and chondrogenesis, from demineralized bone
matrix in skeletal muscle [103], but equally, in combination
with BMP-2, it significantly increased osteogenic differentia-
tion. This was demonstrated in an in vitro model of skeletal
muscle [104] suggesting potential for use in other soft tissues.
In addition, PDGF has been shown in vivo to increase bone
formation and supplement fracture healing [105–107].
Furthermore, Caplan (2011) poses that PDGF-BB is critical
for osteogenesis, in that it has been shown to free pericytes
from their position, allowing an influx of mesenchymal stem
cells (MSCs) to that location and facilitating vascular
reorganisation and replenishment of osteoblasts following
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their natural expiry during bone formation [108]. The use of
PDGF to enhance bone ingrowth in tendon reattachment has
yet to be studied in vivo with most studies focusing on the role
of PDGF in matrix production in the tendon aspect of surgical
repair [38, 109–111]. FGFs have also been implicated in bone
regeneration, despite a general association with fibroblastic
tissues, such as tendons. FGFs are important signalling mole-
cules which regulate endochondral ossification and are fea-
tured heavily in fracture healing [112]. Similar to PDGF, the
application of FGF, specifically FGF-2 (3 μg and 30 μg),
reportedly increases the formation of dense tendon-like tissue
in a rabbit model, with ectopic calcification apparent via
microcomputed tomography [113]. As demonstrated above,
the method of delivery is an important consideration in any
healing intervention, more so when utilising a molecule which
is not inherently osteoinductive.
Kim et al. (2011) investigated the use of TGF-β1 and
TGF-β3 and the enthesis of a repaired rat supraspinatus ten-
don. Utilising an osmotic pump delivery system, Kim et al.
observed an increase in type-III collagen, when compared to
controls, indicative of scar-mediated healing [114]. The
TGF-β3 group demonstrated no differences with paired con-
trols; however, in a following study utilising a heparin-/fibrin-
based vehicle, accelerated healing with associated cell mech-
anisms was observed, specifically associated with soft tissue
healing [115]. In contrast, Kovacevic et al. (2011) utilised a
calcium-phosphate (Ca-P) matrix to deliver 2.75 μg of
TGF-β3 [116] into the supraspinatus tendon of male
Sprague-Dawley rats. In groups with just Ca-P intervention,
new bone, increased fibrocartilage, and matrix organisation
were observed. With the addition of the TGF-β3 to the Ca-
P, the strength of the tendon-bone interface was significantly
improved (4 weeks after intervention) and a more favourable
collagen type-I/type-III ratio, indicative of a more mature
stage of healing.
A peptide consisting of 13 amino acids called Sadat-Habdan
mesenchymal stimulating peptide (SHMSP) was investigated for
use in ACL reconstruction [117] to enhance bone anchorage.
Utilising 20 skeletally mature rabbits, 10 had an intervention of
SHMSP and the remaining 10 rabbits received only a bone tun-
nel repair. In comparison to the control, the SHMPgroup showed
bone formation from 4weekswith extensive new bone growth in
the tunnel by week 8. Whilst this indicates the potential for en-
hanced bone-tendon healing, further work is obviously required
to confirm this result and is acknowledged in the discussion of
the report [117].
Conclusion
From existing research, it can be concluded that BMP-7 has
demonstrated the most effectiveness amongst the BMP
osteoinductive growth factors, when used alone rather than
in combination, with a maximum effect for BMP-7 dosage
of 1000 ng/mL. Use of sustained delivery systems including
GHSs and acellular matrices seem to be imperative in promot-
ing healing as BMPs have short half-lives and require a deliv-
ery system that can maintain their effects continuously, since
this is not always feasible when using local injections or sys-
temic modes of delivery. Acellular dermal matrix grafts not
only have higher suture pull-out strength in comparison to
other extracellular matrix scaffolds but also minimise the
problems associated with graft rejection. Studies have also
explored the use of factors that are not classically associated
with osteoinduction. PDGF, FGF, and TGF-β isoforms, al-
though sometimes associated with properties detrimental to
RCI healing, such as fibrosis and scarring, have shown prom-
ising results when used in combination or in place of BMPs.
However, the delivery method must be carefully considered,
and larger in vivo studies are still required.
A chronic injury model seems most appropriate for research,
with higher relevance when human tenocytes are incorporated
when compared to animal models alone. For the future outlook,
growth factor delivery systems must be designed to provide an
active cell-instructive environment during the therapeutic
healing period. Such a strategy would especially benefit the
geriatric population whose healing mechanism is detrimentally
affected by senescence and degeneration.
Developmental studies using PTHrh have highlighted the
importance of optimising the timing of the delivery of healing
factors, especially regarding inflammatory healing responses.
Further, there is a need for prolonged, in-depth analysis of the
structure and organisation of the Bhealed^ tissues, since the
formation, organisation, and biomechanical properties of the
tissue are paramount to the function of the tissue and avoid-
ance of additional procedures sue to re-tear.
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